Announcements Trials
Browse Landscape

Phase

Phase 3 2

Status

Completed 5Terminated 2Active not recruiting 2Unknown 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Carcinoma, Renal Cell 7Gastrointestinal Stromal Tumors 5Urologic Neoplasms 2Prostatic Neoplasms 2Neoplasm Metastasis 2Multiple Myeloma 2Lymphoma 2Carcinoma 2Uveal Melanoma 1Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Thyroid Neoplasms 1Thymoma 1Stomach Neoplasms 1Sarcoma 1Rectal Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neoplasms by Site 1Neoplasms 1Melanoma 1Lung Neoplasms 1Kidney Neoplasms 1Kidney Diseases 1Hematologic Neoplasms 1Glioma 1Esophageal Neoplasms 1Endometrial Neoplasms 1Colorectal Neoplasms 1

Interventions

Cisplatin 10pembrolizumab 8Carboplatin 8durvalumab 5Pemetrexed 5Paclitaxel 51-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine 5osimertinib 4Specimen Handling 4Magnetic Resonance Spectroscopy 4Taxes 3Gemcitabine 3Bevacizumab 3cabozantinib 2atezolizumab 2Sunitinib 2Radiotherapy, Intensity-Modulated 2Radiotherapy 2Radiation 2Platinum 2Nivolumab 2Immunoglobulin G 2Docetaxel 2Disulfides 2CP protocol 2Biopsy 21,2-diaminocyclohexaneplatinum II citrate 2tremelimumab 1relatlimab 1peposertib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Active not recruiting × Carcinoma × Sunitinib × Clear all
NCT05043090 2026-05-22

SAMETA

AstraZeneca

Phase 3 Active not recruiting
148 enrolled
Genitourinary

Carcinoma, Carcinoma, Renal Cell, Neoplasm Metastasis

NCT03091192 2026-04-14

Savolitinib vs. Sunitinib in MET-driven PRCC.

AstraZeneca

Phase 3 Active not recruiting
60 enrolled 15 charts
Genitourinary

Carcinoma, Carcinoma, Renal Cell, Kidney Diseases, Kidney Neoplasms, Neoplasms by Site, Urologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡